{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:42:47Z","timestamp":1792701767754,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.lungcan.2025.108084","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T17:28:39Z","timestamp":1736443719000},"page":"108084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-2491","authenticated-orcid":false,"given":"Igor","family":"Gomez-Randulfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Scanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-242X","authenticated-orcid":false,"given":"Laura","family":"Moliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-1548","authenticated-orcid":false,"given":"Emine","family":"Cil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blackhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8167-5461","authenticated-orcid":false,"given":"Colin R","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-2665","authenticated-orcid":false,"given":"Fabio","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2025.108084_b0005","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108084_b0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108084_b0015","doi-asserted-by":"crossref","unstructured":"Bg S, E H, P C, M K, Kr L, Jb S, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS\u00a0: acta pathologica, microbiologica, et immunologica Scandinavica [Internet]. 2015 Feb [cited 2024 Feb 19];123(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25421919\/.","DOI":"10.1111\/apm.12328"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108084_b0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non\u2013Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108084_b0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108084_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108084_b0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108084_b0040","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108084_b0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108084_b0050","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108084_b0055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108084_b0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108084_b0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108084_b0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/10781552211020798","article-title":"A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study","volume":"28","author":"Lee","year":"2022","journal-title":"J Oncol Pharm Pract."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108084_b0075","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/cam4.3733","article-title":"Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2025.108084_b0080","series-title":"Sampling Techniques","author":"Cochran","year":"1977"},{"key":"10.1016\/j.lungcan.2025.108084_b0085","unstructured":"Wayne W. D. Biostatistics: A Foundation for Analysis in the Health Sciences. Seventh. New York: John Wiley & sons;."},{"key":"10.1016\/j.lungcan.2025.108084_b0090","unstructured":"NHS England Digital [Internet]. [cited 2024 Jun 11]. Personal Demographics Service. Available from: https:\/\/digital.nhs.uk\/services\/personal-demographics-service."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108084_b0095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/sim.4780100510","article-title":"A comparison of two simple hazard ratio estimators based on the logrank test","volume":"10","author":"Berry","year":"1991","journal-title":"Stat Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108084_b0100","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1214\/aos\/1176346414","article-title":"A Generalized Kaplan-Meier Estimator","volume":"12","author":"Robertson","year":"1984","journal-title":"Ann. Stat."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108084_b0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2288-10-20","article-title":"Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer","volume":"16","author":"Bellera","year":"2010","journal-title":"BMC Med Res Methodol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108084_b0110","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.21037\/tlcr-23-577","article-title":"Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108084_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100115","article-title":"A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903","volume":"6","author":"Ito","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108084_b0120","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaoncol.2018.1395","article-title":"Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Aguiar","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108084_b0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01521","article-title":"Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non\u2013Small-Cell Lung Cancer","author":"Remon","year":"2024","journal-title":"JCO."},{"key":"10.1016\/j.lungcan.2025.108084_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101994","article-title":"The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal","volume":"85","author":"Gristina","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"7878","key":"10.1016\/j.lungcan.2025.108084_b0135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.lungcan.2025.108084_b0140","first-page":"00123","article-title":"Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review","volume":"S1556\u20130864","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108084_b0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108084_b0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oncolo\/oyac022","article-title":"Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)","volume":"27","author":"Popat","year":"2022","journal-title":"Oncologist."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:22:26Z","timestamp":1739164946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"alternative-id":["S0169500225000054"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108084","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108084"}}